Mineralys Therapeutics (MLYS) Stock Overview
A clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MLYS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Mineralys Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.90 |
| 52 Week High | US$47.65 |
| 52 Week Low | US$8.24 |
| Beta | 0.40 |
| 1 Month Change | -22.04% |
| 3 Month Change | -0.54% |
| 1 Year Change | 210.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 100.11% |
Recent News & Updates
Recent updates
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions
Oct 01Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?
Jun 14
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Mar 10Is Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?
Feb 20Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Jan 20Here's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
Oct 07Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Sep 17We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jun 06Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Shareholder Returns
| MLYS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.2% | -1.0% | -0.7% |
| 1Y | 210.1% | 20.4% | 12.6% |
Return vs Industry: MLYS exceeded the US Biotechs industry which returned 19.1% over the past year.
Return vs Market: MLYS exceeded the US Market which returned 13.7% over the past year.
Price Volatility
| MLYS volatility | |
|---|---|
| MLYS Average Weekly Movement | 8.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MLYS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MLYS's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 51 | Jon Congleton | mineralystx.com |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company’s clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension.
Mineralys Therapeutics, Inc. Fundamentals Summary
| MLYS fundamental statistics | |
|---|---|
| Market cap | US$2.85b |
| Earnings (TTM) | -US$171.36m |
| Revenue (TTM) | n/a |
Is MLYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLYS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$171.36m |
| Earnings | -US$171.36m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLYS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/12 14:42 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mineralys Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chen Yang | BofA Global Research |
| Timothy Anderson | BofA Global Research |
| Umer Raffat | Evercore ISI |